Improving Patient Communication in MG
Expert neurologists share thoughts on how to improve patient/physician communication and how listening to the patient needs will aid in managing MG.
The Pharmacist’s Role in MG Management
Drs Howard, Silvestri, Vu, Habib, and Stein comment on the role of pharmacists in managing MG, emphasizing educating both the pharmacists and the patients.
Personalizing Care in MG
Expert neurologists discuss patient-focused care when it comes to treating MG, also highlighting clinical trials.
Emerging Treatments in MG
Neurology experts provide an overview of emerging treatments in MG, highlighting biomarkers and new routes of administration.
Treatment Adherence in MG
Experts in neurology discuss how to ensure disease progression in not due to poor adherence to treatment in MG, emphasizing educating the patient about their disease.
Switching MG Treatment Due to Adverse Events or Poor Disease Control
Expert neurologists share approaches to switching MG treatment due to either poor disease control or adverse events.
Modes of Administration for Targeted Treatment in MG
Experts in neurology review the varied routes of administration of targeted treatment in MG, highlighting intravenous and subcutaneous formulations and how they can provide more patient-centric care.
Use of Targeted Therapies in the Treatment Algorithm of MG
Expert neurologists discuss the treatment algorithm of MG, focusing on the use of targeted therapies as well as barriers to their use.
Targeted Therapy Options in MG
Nicholas Silvestri, MD, FAAN, and Tuan Vu, MD, provide an overview of the current FDA-approved targeted therapies for the treatment of MG.
Quality of Life in MG
Experts in neurology highlight taking age and quality of life into consideration when approaching treatment of MG, as well as comment on the standard of care for patients.
Treatment Approach in MG
Expert neurologists discuss the factors that guide treatment selection in MG, shifting the framework to take patient preferences into account.
Hospitalization of Older Patients in MG
Ali Habib, MD, comments on the prevalence of MG in older patients and the increasing rate of hospitalization and mortality within this group.
Accurate Diagnosis of MG
Beth Stein, MD, reviews critical steps towards diagnosing MG, taking a look at the different types of reliable testing for the disease.
Fatigue and Fluctuating Symptoms in MG
Experts in neurology comment on fatigue and fluctuation of symptoms in MG and how that can contribute to a delay in diagnosis.
Presentation of Myasthenia Gravis (MG)
Expert neurologists discuss the presentation of myasthenia gravis (MG), focusing on the variability of symptoms from patient to patient.
Effects of Combination Therapies, Treatment Adverse Effects in Myasthenia Gravis: Nicholas Silvestri, MD, FAAN
The clinical professor at the University at Buffalo discussed the complexities of using combination therapies to treat myasthenia gravis, and whether adverse events play a major role in treatment decisions. [WATCH TIME: 3 minutes]
Evaluating the Treatment Evolution of Myasthenia Gravis and Use of Immunosuppressants: Nicholas Silvestri, MD, FAAN
The clinical professor of neurology at the University at Buffalo provided insight on the advances in treatment options for patients with myasthenia gravis over the past few decades. [WATCH TIME: 3 minutes]
Unmet Needs and Future Directions in Myasthenia Gravis
James F. Howard Jr., MD, and Nicholas J. Silvestri MD, FAAN, deliver parting thoughts on the state of the myasthenia gravis treatment, focusing on current deficits and future prospects.
Investigational Agents for Myasthenia Gravis
Two subject matter experts discuss promising treatment methods and agents in the pipeline for patients with myasthenia gravis.
FcRns Inhibitors for the Treatment of Myasthenia Gravis
James F. Howard Jr., MD and Nicholas J. Silvestri MD, FAAN, discuss the efficacy and safety of FcRn inhibitors, as well as consider their role in the rapidly evolving treatment landscape.
Complement Inhibitors
Experts discuss the benefits of complement inhibitors in reducing symptoms of myasthenia gravis.
Recently FDA Approved Medications for Myasthenia Gravis
James F. Howard Jr., MD, and Nicholas J. Silvestri MD, FAAN, review the role of complement inhibitors and FcRn inhibitors in the management of myasthenia gravis.
Non-Pharmacological Approaches for to Myasthenia Gravis
Thought leaders review the role of non-pharmacological strategies to manage myasthenia gravis comorbidities.
Drugs to Avoid in Patients With Myasthenia Gravis
A comprehensive review of drugs to avoid when designing treatment plans for patients with myasthenia gravis.
Treatment Approaches in Special Populations with Myasthenia Gravis
Experts recommend approaches for special cases including ocular myasthenia gravis, pregnant patients and children with myasthenia gravis, and more.
Acute Exacerbation of Myasthenia Gravis
Recommendations from neurologists James F. Howard Jr., MD and Nicholas J. Silvestri MD, FAAN for addressing acute exacerbation in patients with myasthenia gravis.
Use of Thymectomy
Two subject matter experts discuss cases where a thymectomy is appropriate for treating patients with myasthenia gravis.
Use of AChEI and Immunosuppressives in Managing Symptoms
James F. Howard Jr., MD and Nicholas J. Silvestri MD, FAAN, share insights regarding acetylcholinesterase inhibitors and immunosuppressive therapy as first-line treatments for patients with myasthenia gravis.
Goals of Therapy and Patient Communication
Thought leaders offer practical advice on setting therapy goals for patients with myasthenia gravis, with an emphasis on patient inclusion.
Misdiagnosis Associated With Myasthenia Gravis and Importance of Multidisciplinary Teams
Expert panelists discuss misdiagnosis of myasthenia gravis and consider the question of whether this condition should be treated by community physicians.